The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Open accessAbstract
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. METHODS: In this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1 ratio to receive vutrisiran (25 mg) or placebo every 12 weeks for up to 36 months. The primary end point was a composite of death from any cause and recurrent cardiovascular events. Secondary end points included death from any cause, the change from baseline in the distance covered on the 6-minute walk test, and the change from baseline in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score. The efficacy end points were assessed in the overall population and in the monotherapy population (the patients who were not receiving tafamidis at baseline) and were tested hierarchically. RESULTS: A total of 655 patients underwent randomization; 326 were assigned to receive vutrisiran and 329 to receive placebo. Vutrisiran treatment led to a lower risk of death from any cause and recurrent cardiovascular events than placebo (hazard ratio in the overall population, 0.72; 95% confidence interval [CI], 0.56 to 0.93; P = 0.01; hazard ratio in the monotherapy population, 0.67; 95% CI, 0.49 to 0.93; P = 0.02) and a lower risk of death from any cause through 42 months (hazard ratio in the overall population, 0.65; 95% CI, 0.46 to 0.90; P = 0.01). Among the patients in the overall population, 125 in the vutrisiran group and 159 in the placebo group had at least one primary end-point event. In the overall population, treatment with vutrisiran resulted in less of a decline in the distance covered on the 6-minute walk test than placebo (least-squares mean difference, 26.5 m; 95% CI, 13.4 to 39.6; P<0.001) and less of a decline in the KCCQ-OS score (least-squares mean difference, 5.8 points; 95% CI, 2.4 to 9.2; P<0.001). Similar benefits were observed in the monotherapy population. The incidence of adverse events was similar in the two groups (99% in the vutrisiran group and 98% in the placebo group); serious adverse events occurred in 62% of the patients in the vutrisiran group and in 67% of those in the placebo group. CONCLUSIONS: Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B ClinicalTrials.gov number, NCT04153149.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationNonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore, J. D., Maurer, M. S., Falk, R. H., Merlini, G., Damy, T., Dispenzieri, A., Wechalekar, A. D., Berk, J. L., Quarta, C. C., Grogan, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.021612 · Cited by 2,081
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., Burazor, I., Caforio, A. L. P., Damy, T., Eriksson, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab072 · Cited by 1,231
Self-citationTransthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
A new staging system for cardiac transthyretin amyloidosis
Gillmore, J. D., Damy, T., Fontana, M., Hutchinson, M., Lachmann, H. J., Martinez-Naharro, A., Quarta, C. C., Rezk, T., Whelan, C. J., Gonzalez-Lopez, E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx589 · Cited by 776
Self-citationInterpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care
Spertus, J. A., Jones, P. G., Sandhu, A. T., & Arnold, S. V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.542 · Cited by 619
Maurer, M. S., Bokhari, S., Damy, T., Dorbala, S., Drachman, B. M., Fontana, M., Grogan, M., Kristen, A. V., Lousada, I., Nativi-Nicolau, J., et al. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006075 · Cited by 568
Self-citationEfficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Gillmore, J. D., Judge, D. P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., Grogan, M., Hanna, M., Hoffman, J., Masri, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305434 · Cited by 546
Self-citationGenotype and Phenotype of Transthyretin Cardiac Amyloidosis
Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.596 · Cited by 538
Self-citationHereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Adams, D., Tournev, I. L., Taylor, M. S., Coelho, T., Planté-Bordeneuve, V., Berk, J. L., González-Duarte, A., Gillmore, J. D., Low, S.-C., Sekijima, Y., et al. (2023) · Amyloid · doi:10.1080/13506129.2022.2091985 · Cited by 406
Self-citationCoelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Self-citationPatisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Self-citationRapezzi, C., Quarta, C. C., Obici, L., Perfetto, F., Longhi, S., Salvi, F., Biagini, E., Lorenzini, M., Grigioni, F., Leone, O., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs123 · Cited by 332
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
Ioannou, A., Patel, R. K., Razvi, Y., Porcari, A., Sinagra, G., Venneri, L., Bandera, F., Masi, A., Williams, G. E., O’Beara, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060852 · Cited by 245
Self-citationHabtemariam, B. A., Karsten, V., Attarwala, H., Goel, V., Melch, M., Clausen, V. A., Garg, P., Vaishnaw, A. K., Sweetser, M. T., Robbie, G. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1974 · Cited by 176
Self-citationKeam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01765-5 · Cited by 158
Mixtures of multiple testing procedures for gatekeeping applications in clinical trials
Dmitrienko, A. A., & Tamhane, A. C. (2011) · Statistics in Medicine · doi:10.1002/sim.4008 · Cited by 61
García‐Pavía, P., Grogan, M. A., Kale, P. P., Berk, J. L., Maurer, M. S., Conceição, I. M., Carli, M. F. D., Solomon, S. D., Chen, C., Yureneva, E., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3138 · Cited by 58
Self-citationA Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
González‐Duarte, A., & Ulloa‐Aguirre, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313158 · Cited by 51
General theory of mixture procedures for gatekeeping
Dmitrienko, A. A., & Tamhane, A. C. (2013) · Biometrical Journal · doi:10.1002/bimj.201100258 · Cited by 29
González‐Moreno, J., Dispenzieri, A. A., Grogan, M. A., Coelho, T., Tournev, I., Waddington‐Cruz, M., Wixner, J., Diemberger, I., García‐Pavía, P., Chapman, D., et al. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00344-3 · Cited by 28
Self-citation
Cited by
Oikonomou, E. K., Sangha, V., Vasisht Shankar, S., Coppi, A., Krumholz, H. M., Nasir, K., Miller, E. J., Gallegos-Kattan, C., Al-Mallah, M. H., Al-Kindi, S., et al. (2024) · doi:10.1101/2024.08.25.24312556 · Cited by 7
AmyloGram reveals amyloidogenic potential in stroke thrombus proteomes
Kell, D. B., Doyle, K. M., Salcedo-Sora, J. E., Sekhar, A., Walker, M., & Pretorius, E. (2025) · Biochemical Journal · doi:10.1042/bcj20253317 · Cited by 4
Metadata
- Authors
- Fontana, M., Berk, J. L., Gillmore, J. D., Witteles, R. M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., Solomon, S. D., Sheikh, F. H., Tahara, N., González-Costello, J., Tsujita, K., Morbach, C., Pozsonyi, Z., Petrie, M. C., Delgado, D., Van der Meer, P., Jabbour, A., Bondue, A., Kim, D., Azevedo, O., Hvitfeldt Poulsen, S., Yilmaz, A., Jankowska, E. A., Algalarrondo, V., Slugg, A., Garg, P. P., Boyle, K. L., Yureneva, E., Silliman, N., Yang, L., Chen, J., Eraly, S. A., Vest, J., & Maurer, M. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-02
- Volume
- 392
- Issue
- 1
- Pages
- 33-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402058291
- Cited by
- 462
- References
- 24
- FWCI
- 53.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.